You are here

  • Home
  • Archive
  • Volume 7, Issue 1
  • First-in-human phase 1 study of IT1208, a defucosylated humanized anti-CD4 depleting antibody, in patients with advanced solid tumors

Article metrics

Article menu

Download PDFPDF

XML
Research Article
First-in-human phase 1 study of IT1208, a defucosylated humanized anti-CD4 depleting antibody, in patients with advanced solid tumors

 

Online download statistics by month:

Online download statistics by month: December 2019 to September 2025

AbstractFullPdf
Dec 2019440
Jan 202013130
Feb 202031313
Mar 202028284
Apr 202015152
May 202037372
Jun 202028288
Jul 2020313150
Aug 2020242422
Sep 2020505041
Oct 2020414131
Nov 2020363624
Dec 2020292926
Jan 2021444421
Feb 2021232314
Mar 2021373727
Apr 2021292923
May 2021262628
Jun 2021444432
Jul 2021464631
Aug 2021282819
Sep 2021454529
Oct 2021282842
Nov 2021343439
Dec 2021373717
Jan 2022333411
Feb 2022414127
Mar 2022373726
Apr 2022424324
May 2022262726
Jun 2022202013
Jul 202225256
Aug 2022222217
Sep 2022293221
Oct 2022202318
Nov 2022293130
Dec 2022252515
Jan 2023262610
Feb 2023313114
Mar 2023323316
Apr 2023181812
May 2023363616
Jun 2023212111
Jul 2023252518
Aug 2023363617
Sep 2023181813
Oct 2023313114
Nov 2023273016
Dec 2023292916
Jan 2024454516
Feb 2024404022
Mar 2024383818
Apr 2024323216
May 2024353722
Jun 2024363719
Jul 2024363616
Aug 2024505022
Sep 2024252679
Oct 20242424143
Nov 2024404226
Dec 2024837920
Jan 2025676844
Feb 202512612615
Mar 2025747423
Apr 2025858519
May 2025464630
Jun 2025373721
Sep 2025220
Total238824061513